M A C Onuigbo

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Nondialytic therapy for end-stage renal disease is an underutilized care paradigm in the United States: time for a more robust reappraisal of this treatment option
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Wisconsin, USA
    Adv Perit Dial 29:73-6. 2013
  2. doi request reprint Evidence of the syndrome of rapid onset end-stage renal disease (SORO-ESRD) in the acute kidney injury (AKI) literature--preventable causes of AKI and SORO-ESRD--a call for re-engineering of nephrology practice paradigms
    Macaulay A C Onuigbo
    Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Ren Fail 35:796-800. 2013
  3. doi request reprint The CKD enigma with misleading statistics and myths about CKD, and conflicting ESRD and death rates in the literature: results of a 2008 U.S. population-based cross-sectional CKD outcomes analysis
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Ren Fail 35:338-43. 2013
  4. doi request reprint Renoprevention: A new concept for reengineering nephrology care--an economic impact and patient outcome analysis of two hypothetical patient management paradigms in the CCU
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN 54702, USA
    Ren Fail 35:23-8. 2013
  5. doi request reprint De novo HBV infection in a Mayo Clinic hemodialysis population: economic impact of reduced HBV testing and a call for changes in current US CDC guidelines on HBV testing protocols
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, Minnesota 54702, USA
    Hemodial Int 16:S32-8. 2012
  6. ncbi request reprint Newly symptomatic central diabetes insipidus in ESRD with adult polycystic kidney disease following intracranial hemorrhage: the first reported case
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Med Sci Monit 16:CS29-32. 2010
  7. doi request reprint Hepatitis B surface antigenemia following recombinant Engerix B hepatitis B vaccine in an 81-year-old ESRD patient on hemodialysis
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Ren Fail 32:531-2. 2010
  8. doi request reprint Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRD
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Ren Fail 32:954-8. 2010
  9. doi request reprint Non-dilated obstructive uropathy - an unrecognized cause of acute renal failure in hospitalized US patients: three case reports seen over 6 months in a northwestern Wisconsin nephrology practice
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Ren Fail 32:1226-9. 2010
  10. doi request reprint Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients?
    Macaulay A C Onuigbo
    College of Medicine, Mayo Health System Practice Based Research Network, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Nephron Clin Pract 118:c407-19. 2011

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Nondialytic therapy for end-stage renal disease is an underutilized care paradigm in the United States: time for a more robust reappraisal of this treatment option
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Wisconsin, USA
    Adv Perit Dial 29:73-6. 2013
    ..S. nephrology practices. The place of NDT, actively provided by a specialized multidisciplinary team, for U.S. ESRD patients demands urgent attention and robust reappraisal by U.S. nephrologists...
  2. doi request reprint Evidence of the syndrome of rapid onset end-stage renal disease (SORO-ESRD) in the acute kidney injury (AKI) literature--preventable causes of AKI and SORO-ESRD--a call for re-engineering of nephrology practice paradigms
    Macaulay A C Onuigbo
    Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Ren Fail 35:796-800. 2013
    ..It remains unclear to what extent this syndrome may have been identified in the past without acknowledging its uniqueness...
  3. doi request reprint The CKD enigma with misleading statistics and myths about CKD, and conflicting ESRD and death rates in the literature: results of a 2008 U.S. population-based cross-sectional CKD outcomes analysis
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Ren Fail 35:338-43. 2013
    ..Finally, the clear heterogeneity of the so-called CKD patient is brought into prominence as we review the very misleading concept of classifying and prognosticating all CKD patients as one homogenous patient population...
  4. doi request reprint Renoprevention: A new concept for reengineering nephrology care--an economic impact and patient outcome analysis of two hypothetical patient management paradigms in the CCU
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN 54702, USA
    Ren Fail 35:23-8. 2013
    ..We recently described a new syndrome of ESRD following AKI, the syndrome of rapid-onset end-stage renal disease (SORO-ESRD). Renoprevention, which we described in 2009, is the application of preventative measures to reduce AKI incidence...
  5. doi request reprint De novo HBV infection in a Mayo Clinic hemodialysis population: economic impact of reduced HBV testing and a call for changes in current US CDC guidelines on HBV testing protocols
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, Minnesota 54702, USA
    Hemodial Int 16:S32-8. 2012
    ..The US CDC should revise these outdated guidelines, last revised in 2001, to fall in line with current clinical realities on the ground...
  6. ncbi request reprint Newly symptomatic central diabetes insipidus in ESRD with adult polycystic kidney disease following intracranial hemorrhage: the first reported case
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Med Sci Monit 16:CS29-32. 2010
    ..However, there have been published a few reports of the unmasking of polyuria secondary to previously existing CDI in ESRD patients, after kidney transplantation...
  7. doi request reprint Hepatitis B surface antigenemia following recombinant Engerix B hepatitis B vaccine in an 81-year-old ESRD patient on hemodialysis
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Ren Fail 32:531-2. 2010
    ..This is particularly important in HD units where hepatitis B screening is carried out routinely all year round and hepatitis B vaccinations are commonplace. Very strict schedules must be adopted to avoid false positive HBsAg tests...
  8. doi request reprint Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRD
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Ren Fail 32:954-8. 2010
    ..If confirmed to represent a significant proportion of the ESRD population, at least here in the United States, this finding will demand major paradigm shifts in the current concepts of reno-protection and "A-V Fistula first" programs...
  9. doi request reprint Non-dilated obstructive uropathy - an unrecognized cause of acute renal failure in hospitalized US patients: three case reports seen over 6 months in a northwestern Wisconsin nephrology practice
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Ren Fail 32:1226-9. 2010
    ..One required temporary hemodialysis. We submit that NDOU may be more common than previously speculated. A high index of suspicion is warranted as significant renal salvage can often be achieved by timely decompression procedures...
  10. doi request reprint Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients?
    Macaulay A C Onuigbo
    College of Medicine, Mayo Health System Practice Based Research Network, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Nephron Clin Pract 118:c407-19. 2011
    ..This represents the concept of renoprevention...
  11. doi request reprint Bilateral lower extremity sequential compression devices (SCDs): a novel approach to the management of intra-dialytic hypotension in the outpatient setting--report of a case series
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Ren Fail 32:32-5. 2010
    ..This novel modality of managing IDH is complementary to other standard therapies. Larger multi-center studies are warranted...
  12. ncbi request reprint Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Adv Perit Dial 25:89-91. 2009
    ..Pragmatic tactics of this kind will avoid significant morbidity and mortality. In addition, this approach will save millions of now increasingly scarce health care dollars...
  13. ncbi request reprint Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience
    Macaulay A C Onuigbo
    Department of Nephrology, Midelfort Clinic, Mayo Health System, Eau Claire, WI 54702, USA
    Med Sci Monit 11:CR462-9. 2005
    ..The worldwide ESRD epidemic, coincident with increasing use of AB, prompted us to hypothesize a late-onset azotemia in such CKD patients...
  14. doi request reprint Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients
    Macaulay A C Onuigbo
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Int Urol Nephrol 40:233-9. 2008
    ..Given concerns for iatrogenic CKD/ESRD, we designed a prospective study to analyze the course of eGFR following withdrawal of AB in such patients...
  15. doi request reprint Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors
    Macaulay A C Onuigbo
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Ren Fail 30:73-80. 2008
    ..We submit that microvascular renal arteriolar narrowing is the pathophysiologic mechanism. These observations call for further study...
  16. doi request reprint Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis
    M A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    QJM 101:519-27. 2008
    ..Current literature regarding worsening renal failure in CKD patients with RAS is based almost wholly on retrospective studies, and therefore may be poorly understood...
  17. doi request reprint Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: an extended Mayo Clinic prospective 63-month experience
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Ren Fail 30:363-71. 2008
    ..S. population. An aging U.S. population further raises the probability of the presence of increasing and unrecognized renal artery stenosis in our CKD patient population...
  18. doi request reprint Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET--a call for more circumspection
    M A C Onuigbo
    Department of Nephrology, Midelfort Clinic, Mayo Health System, 1221 Whipple Street, Eau Claire, WI 54702, USA
    QJM 102:155-67. 2009
    ..Such preventative measures (reno-prevention) would enhance the benefits of reno-protection with RAAS blockade...
  19. doi request reprint Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution
    Macaulay A Onuigbo
    Midelfort Clinic, Mayo Health System, Eau Claire, Wisc 54702, USA
    Nephron Clin Pract 113:c63-9, discussion c70. 2009
    ..Combination ACEI + ARB therapy should be the exception, rather than the rule. Temporary withdrawal of ACEI/ARB before certain exposures, 'renoprevention', would only further improve the results of renoprotection...
  20. doi request reprint Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wiscons
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Hemodial Int 13:S24-9. 2009
    ....
  21. ncbi request reprint The natural history of chronic kidney disease revisited--a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: a ca
    Macaulay A C Onuigbo
    College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Adv Perit Dial 25:85-8. 2009
    ..This author agrees with researchers who recently emphasized the heterogeneity of the CKD population. Patient prognosis and management must be individualized...
  22. ncbi request reprint Evidence-based treatment of hypertension in patients with diabetes mellitus
    M Onuigbo
    Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
    Diabetes Obes Metab 5:13-26. 2003